Hylomorph

Hylomorph is a clinical-stage med-tech company founded in 2014 as a spin-off from ETH Zurich, Switzerland. Headquartered in Technopark Zurich, the company is led by co-founders Simone Bottan, Aldo Ferrari, and Francesco Robotti. Hylomorph's mission is to enhance patient outcomes by preventing complications associated with implantable medical devices. The company specializes in innovative medical devices and drug-device combinations that improve the biocompatibility of implants. Their flagship product, the Hylomate Pouch, is an implantable pouch made from micro-engineered biosynthetic cellulose, designed to fit cardiac implantable electronic devices like pacemakers. This pouch provides a protective envelope around the device to reduce post-surgical complications. Hylomorph aims to set new standards for infection prevention across various medical implants, enhancing patient safety and reducing healthcare costs. The company has secured funding through multiple rounds and grants, and collaborates with clinical advisors from leading medical institutions to advance its innovations in preventive medicine.

• Employees9
• Founded2015
• Annual Revenue$2500000
• Total Funding$17825098